Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Alzheimer's disease
MedTech
Beckman Coulter grows Alzheimer’s dx portfolio with CE mark
Beckman Coulter expanded its portfolio of Alzheimer’s disease diagnostics by earning a CE mark in Europe for its Access p-Tau217 assay.
Joseph Keenan
Jul 7, 2026 10:55am
Merck halts ph. 2 Alzheimer’s trial after underwhelming efficacy
Jul 1, 2026 2:35pm
Backed by top VCs, biotech bags Alzheimer’s med in $2.2B deal
Jul 1, 2026 4:40am
Fierce Pharma
Fosun Pharma plots global push, fueled by Alzheimer’s deals
Jun 25, 2026 7:00pm
Abbott pens blood-based Alzheimer's testing deal with ALZpath
Jun 24, 2026 9:02am
Novartis ‘always looking’ for new ways to shuttle drugs to brain
May 28, 2026 8:44am
